Trials / Unknown
UnknownNCT01728025
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Tel-Aviv Sourasky Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranolazine |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2012-11-16
- Last updated
- 2015-03-26
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01728025. Inclusion in this directory is not an endorsement.